FOXO3 and acute myeloid leukemia: Moreover, overexpression of FOXO3 is associated with reduced overall survival and progression-free survival in patients with acute myelogenous leukemia and with poor prognosis in patients with pancreatic ductal adenocarcinoma and glioblastoma (72–74).